Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

"The article proposes screening repurposed drugs for phospholipidoasis as a predictor of poor Covid 19 performance.

Since an antiviral has not been found to be effctive researchers could have screened for any biologic entity and would have come up with the same result."

Thanks for your reply, but I don't think you did understand the implications of the research the article highlights.

I'm not suggesting that brilacidin should be tested for its in vitro MoA at this stage.

I agree that we should instead wait and see the results of the study.

I'm instead suggesting that it's plausible given what we know about brilacidin's membrane depolarisation and destabilisation mechanism that the positive in vitro results seen are in fact due to in-vitro phospholipidosis in the cell lines tested, then the chances are that brilacidin would miss the primary endpoint.

I agree with you however that we will know the answer to that in a relatively short time frame.